MDA7: a novel selective agonist for CB2receptors that prevents allodynia in rat neuropathic pain models

Publisher Website
Google Scholar
Abstract
Background and purpose: There is growing interest in using cannabinoid type 2 (CB2) receptor agonists for the treatment of neuropathic pain. In this report, we describe the pharmacological characteristics of MDA7 (1‐[(3‐benzyl‐3‐methyl‐2,3‐dihydro‐1‐benzofuran‐6‐yl)carbonyl]piperidine), a novel CB2receptor agonist.Experimental approach: We characterized the pharmacological profile of MDA7 by using radioligand‐binding assays andin vitrofunctional assays at human cannabinoid type 1 (CB1) and CB2receptors.In vitrofunctional assays were performed at rat CB1and CB2receptors. The effects of MDA7 in reversing neuropathic pain were assessed in spinal nerve ligation and paclitaxel‐induced neuropathy models in rats.Key results: MDA7 exhibited selectivity and agonist affinity at human and rat CB2receptors. MDA7 treatment attenuated tactile allodynia produced by spinal nerve ligation or by paclitaxel in a dose‐related manner. These effects were selectively antagonized by a CB2receptor antagonist but not by CB1or opioid receptor antagonists. MDA7 did not affect rat locomotor activity.Conclusion and implications: MDA7, a novel selective CB2agonist, was effective in suppressing neuropathic nociception in two rat models without affecting locomotor behaviour. These results confirm the potential for CB2agonists in the treatment of neuropathic pain.British Journal of Pharmacology(2008)155, 1104–1116; doi:10.1038/bjp.2008.340; published online 1 September 2008